Medindia LOGIN REGISTER
Medindia
Advertisement

Echo Therapeutics Initiates Clinical Study of Its Symphony(TM) Transdermal Continuous Glucose Monitoring System in Patients with Type 1 and Type 2 Diabetes

Wednesday, July 2, 2008 General News
Advertisement
FRANKLIN, Mass., July 1 Echo Therapeutics, Inc.(OTC Bulletin Board: ECTE) announced today that it has initiated a clinicalstudy of its Symphony(TM) Transdermal Continuous Glucose Monitoring System(tCGM System) in patients with Type 1 and Type 2 diabetes. The Companyexpects to complete and announce the results of the study in the third quarterof 2008. Echo's non-invasive Symphony tCGM System consists of its Prelude(TM)SkinPrep System, which incorporates patented and leading-edge skin permeationcontrol technology, and wireless transmission and proprietary transdermalbiosensor technologies. Echo's Symphony tCGM System is designed to provideboth diabetes and hospital patients with a reliable, needle-free, easy-to-use,affordable and comfortable-to-wear continuous glucose monitoring device.
Advertisement

"Building on the momentum generated from our prior four positive pilotclinical studies, we are excited to have started our next pilot study in theimportant diabetes home use market. Our new Prelude Skin Prep System is acompetitively unique component of our Symphony tCGM System, enabling oursystem to generate painless, needle-free, continuous glucose measurements. Theprimary purpose of this new study is to evaluate the performance of ourSymphony tCGM System with Prelude as the new skin permeation element," statedPatrick T. Mooney, M.D., Echo's Chairman and Chief Executive Officer. "We arevery excited about our significant development progress thus far, and we lookforward to making additional progress with Symphony throughout 2008."
Advertisement

Echo's pilot clinical study will enroll ten (10) patients with diabetes(either Type 1 or Type 2) and will compare data obtained from its SymphonytCGM System with both the "gold standard" YSI Glucose Analyzer and awidely-used, commercially available "finger-stick" glucometer. The study willcollect more than 900 data pairs to be used in the analyses. Referenceglucose measurements will be made at 15 minute intervals for 24 hours with thestudy data blinded to study subjects and study personnel.

About Echo Therapeutics

Echo Therapeutics is focused on medical devices and specialtypharmaceuticals. Echo is developing a non-invasive, wireless, transdermalcontinuous glucose monitoring (tCGM) system for patients with diabetes and foruse in hospital critical care units, together with a wide range of noveltopical reformulations of widely-used, FDA-approved products.

Cautionary Statement Regarding Forward Looking Statements

Any statements contained in this press release that do not describehistorical facts may constitute forward-looking statements as that term isdefined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but aresubject to a number of risks and uncertainties. The factors that could causeactual future results to differ materially from current expectations include,but are not limited to, risks related to regulatory approvals and the successof Echo's ongoing studies regarding the efficacy of Echo's Symphony tCGMSystem, the failure of future development and preliminary marketing effortsrelated to Echo's tCGM systems, risks and uncertainties relating to Echo'sability to develop, market and sell diagnostic products based on its skinpermeation platform technologies, including the Prelude SkinPrep System, theavailability of substantial additional equity or debt capital to support itsresearch, development and product commercialization activities, and thesuccess of its research, development, and regulatory approval, marketing anddistribution plans and strategies, including those plans and strategiesrelated to its tCGM systems. Furthermore, Echo's tCGM system has not yet beenapproved for sale. The regulatory approval process for its tCGM systeminvolves, among other factors, successfully completing pilot and pivotalclinical trials
Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close